ARS Pharmaceuticals Shares Slide as Commercial Insurers Hold Out

Despite ongoing negotiations with payers that extended through mid-June, the company reported no new commercial coverage decisions. The setback arrives even as ARS Pharma confirms that Neffy has secured inclusion in Florida state Medicare plans. To offset the stalled commercial momentum, management has tightened its belt, reducing projected full-year cash-based operating expenses to approximately $248 million.

Company leadership maintains that demand for the product continues to climb independently of insurance mandates. To bypass the current coverage gaps, ARS Pharma is leaning on a direct-to-consumer retail cash option priced to compete with existing epinephrine alternatives. Even with the current market volatility, the firm reaffirmed its long-term financial roadmap, targeting cashflow breakeven by 2027.